Quoting the complaint, the Commission said that “such excessive workload has led to severe mental and physical stress, suicides, and dropouts, as also noted by the NMC’s National Task Force (2024).”
The vaccine received approval from the Subject Expert Committee under the Drug Controller General of India (DCGI) for use in people aged 4 to 60 years on April 11.
The researchers said the findings show the direct economic benefits of tobacco cessation and that tobacco control needs to be integrated with poverty reduction strategies.